Senator Dodd (CT) Questions Handling Of Anthrax Complaint
By Thomas D. Williams
The Hartford Courant
March 09, 2001
U.S. Sen. Christopher Dodd is questioning how the Pentagon's
Inspector General handled a complaint by two Connecticut Air
Force Reserve majors that two high-ranking Army officers gave
false or misleading testimony. The dispute centers on a drug
manufacturer's application for a license to make the anthrax
vaccination being given to service members to protect them
against biological warfare.
The military has been inoculating service members since early
1998, even though the manufacturer's existing license describes
the vaccine's use for humans exposed to anthrax-infected animals.
The license request, if granted, would officially cover use of
the vaccine for humans exposed to airborne anthrax spores.
Connecticut Air Force Reserve Majs. Russell Dingle and Thomas
Rempfer say the application, filed in September 1996 and still
pending, shows the vaccine has not been proved effective against
airborne anthrax. They filed their complaint against two Army
officers who they say misrepresented the status of the license
application to cover up its significance in separate testimony
before a Canadian military court and the Senate Armed Services
Committee.
Dodd, a Connecticut Democrat, is asking the inspector general's
office to explain why its officials forwarded the complaint
against the two Army officers back to the very office that
supports and lobbies for the program. "These allegations are
serious," Dodd said, "and they need to be addressed."
A spokesman for the inspector general said Thursday that Deputy
Inspector General Robert J. Lieberman is taking Dodd's request
"very seriously," and is preparing an answer. Three
weeks after receiving the allegations against the two officers in
January, Leonard Trahan Jr., assistant director of the IG's
Hotline, forwarded the inquiry to the senior adviser to the
deputy secretary of defense for chemical and biological
protection.
For the past three years, that office has defended against scores
of claims that the vaccination program is causing sickness.
Military members who resist taking the inoculations have faced
punishment; many others, especially in the reserve and National
Guard, have quit rather than take the anthrax vaccination.
Dingle and Rempfer filed their complaint against Lt. Gen. Ronald
Blanck, the former Army surgeon general who has since retired,
and Col. Arthur Friedlander, an Army medical supervisor who has
been closely involved in vaccine testing and administration. Blanck
told the Senate Armed Services Committee in April 2000 that a
1996 license application for another protective use of the drug
"is really for the [new BioPort manufacturing] facility, not
for the vaccine per se." Blanck was referring to BioPort's
pending application to operate a new manufacturing facility.
Contacted by The Courant, Blanck continued to insist the license
is for the facility, and not needed for the vaccine. He did not
acknowledge the existence of a separate, pending 1996 license
application renewed specifically for protection against
biological warfare. Kim Root, a BioPort spokeswoman, said the
1996 vaccine license application is not a part of the application
for a licensed new facility, and is still pending approval.
Dingle and Rempfer say if Blanck had informed the senators the
Pentagon had sought a new license application, it was highly
likely the senators would want to know why the present license is
insufficient, in turn leading to further investigation of the
anthrax vaccine program.
Friedlander testified before Canadian Military Judge G. L. Brais
last March 30. He was then an expert witness at the court martial
of a Canadian soldier for refusing to take the anthrax vaccine. A
court transcript shows Friedlander denied knowing anything about
the manufacturer's new license application, supervised in part by
the Army medical office where he works. Friedlander refused to
concede that the anthrax vaccine was licensed only for skin
exposure to anthrax, and not for exposures through the lungs.
Source: http://www.ctnow.com/scripts/editorial.dll?bfromind=47&eeid=4120793&eetype=article&render=y&ck=&ver=2.5